Abstract
Background Tumour necrosis factor inhibitors (TNFi) were the first biologics approved for the treatment of psoriasis (PsO) and psoriatic arthritis (Ps......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
